Axovant Gene Therapies Ltd.
http://www.axovant.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Axovant Gene Therapies Ltd.
Moving Cell And Gene Therapies Into Chronic Conditions Depends On Durability, Safety
Biopharma executives discussed their strategies for treating chronic diseases during the Cell and Gene Meeting on the Mesa, including R&D and regulatory considerations.
Early Promise From Axovant’s Parkinson’s Gene Therapy
Gene therapy shows promise in treating movement disorders in 4 patients, matching longer-term results from rivals Neurocrine Biosciences and Voyager Therapeutics.
Finance Watch: 2020 Cell And Gene Therapy Funding Already Bests 2019
Private Company Edition: The Alliance for Regenerative Medicine’s half-year report shows the sector raised $10.7bn in the first half of 2020 versus $9.8bn raised in all of 2019. Also, DCVC Bio closed a $350m fund, new incubator opportunities and VC mega-deals for Dyne and Atomwise.
Finance Watch: VC Mega-Rounds For Machine Learning, CNS Disorders, Academic Discoveries
Private Company Edition: Arvelle, insitro, AbCellera and the University of Michigan have something in common – they each attracted more than $100m in venture capital investment.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- Arvelle Therapeutics GmbH
- Axovant Sciences GmbH
- Axovant Sciences, Inc.
- Axovant Sciences Ltd.
- Roivant Neurosciences Ltd.